

C₂ 23. (Amended) The method of claim 1 wherein said CD40 ligand-enhanced cell is a pathogenic cell.

C₃ 28. (Amended) The method of claim 1 wherein said CD40 ligand-enhanced cell is substantially unable to divide in vitro.

29. (Amended) The method of claims 1 wherein said vaccine composition is attenuated.

C₄ 70. (Amended) The method of claim 23, wherein said vaccine composition further comprises an opsonin-enhanced pathogenic cell, wherein said opsonin of said opsonin pathogenic cell is selected from the group consisting of mannose binding protein and the alpha' chain of c3b.

REMARKS

Pending claims

Claims 1-70 are pending. Claims 15-16, 19, 20, 27, and 30-68 are withdrawn from consideration. Claims 2, 18, and 69 are cancelled. Upon entry of this Amendment and Response, claims 1-14, 17, 22-25, 28-29, 70 are presented for examination. No new matter is added by this amendment. Support for the amended claims is found in the specification and claims as filed.

The present invention relates to a method for the vaccination of a mammal to a selected antigen, wherein the method comprises administering to the animal a vaccine composition comprising a CD40 ligand-enhanced cell. A CD40 ligand-enhanced cell, according to the present invention is a cell comprising the antigen to which the mammal is to be vaccinated, and the cell is further in admixture with an engineered CD40 ligand.

Formal Matters

Priority Claim